Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, Biotech Showcase Conference in San Francisco and the Global Biopharma Symposium hosted by Jones Day & MSQ Ventures.

The Jones Day & MSQ Ventures Pre-JPM Symposium builds impactful partnerships for top leaders and investors in the biotechnology and pharmaceutical sectors, providing an opportunity to gain insight into the latest industry trends. The Biotech Showcase brings more than 400 selected global companies together, covering diverse fields such as innovative biopharmaceuticals, biotechnology platforms, digital health and diagnosis, attracting investors with more than USD 400 billion capital and active partners in the life science field.

After the conference, Dr. Huiming Li interacted with a number of well-known pharmaceutical companies and investment institutions, introducing the Company's pipeline, such as GB05 "Human Interferon α1b Inhalation Solution", GB18 for tumor cachexia (target: GDF-15), GB12 for atopic dermatitis (target: IL-4R/IL-31R), GB19 for lupus erythematosus (target: BDCA2), and GB24 (TL1A bispecific-antibody) for inflammatory bowel disease.

Among them, GB12, GB18 and GB24 have received much attention. For GB24, one of its targets is TL1A, a popular target in the field of inflammatory bowel disease (IBD) that has seen several major transactions recently. In addition to TL1A, GB24 also targets another emerging pathway in IBD that has strong synergistic effects with TL1A in terms of function and mechanism of action, and may help to improve IBD treatment in a profound way. GB24 could be a high-quality innovative asset of Kexing Biopharm among its innovative pipelines.

At this Conference, the rising influence of Chinese innovation in biopharma has become an undeniable trend. Pipelines of drugs invented in China have attracted investment from MNCs and venture capital, leading to multiple cross-border licensing deals in the past year. High quality and innovative science, cost-benefit and speed are among the major contributing factors. It is evident that the innovation ability of Chinese biotechs has been gradually recognized, and this will trigger an uptick in global collaboration in the biopharma industry.

Adhering to the platform-based development strategy of "innovation + internationalization", Kexing Biopharm has accelerated its R&D and innovation since it was listed on the Shanghai Stock Exchange STAR Market, transforming its pipeline portfolio from modified drugs to innovative new drugs. With the advancement of various projects in antiviral, antitumor, and autoimmune research, there is hope to address more clinical gaps.

 

Source: prnewswire.com

Report Abuse